BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21832229)

  • 1. Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
    Tan IL; McArthur JC; Clifford DB; Major EO; Nath A
    Neurology; 2011 Sep; 77(11):1061-7. PubMed ID: 21832229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
    Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
    Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
    Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Too much of a good thing? IRIS with natalizumab-associated PML.
    Berger JR
    Neurology; 2011 Sep; 77(11):1033-4. PubMed ID: 21832217
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Landi D; De Rossi N; Zagaglia S; Scarpazza C; Prosperini L; Albanese M; Buttari F; Mori F; Marfia GA; Sormani MP; Capra R; Centonze D;
    Neurology; 2017 Mar; 88(12):1144-1152. PubMed ID: 28228569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
    Tan LA; Lopes DK
    J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differential diagnosis of immune reconstitution inflammatory syndrome and progressive multifocal leukoencephalopathy after natalizumab withdrawal].
    Yakushina TI; Yakushin DM; Shtang IO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):116-121. PubMed ID: 36946407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract]   [Full Text] [Related]  

  • 14. To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.
    Scarpazza C; Prosperini L; De Rossi N; Moiola L; Sormani MP; Gerevini S; Capra R;
    Ann Neurol; 2017 Nov; 82(5):697-705. PubMed ID: 29023856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
    Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments.
    Bernard-Valnet R; Moisset X; Maubeuge N; Lefebvre M; Ouallet JC; Roumier M; Lebrun-Frenay C; Ciron J; Biotti D; Clavelou P; Godeau B; Du Pasquier RA; Martin-Blondel G
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34728496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
    Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
    Hellwig K; Kleiter I; Gold R
    Neurology; 2012 Jan; 78(5):371; author reply 371. PubMed ID: 22291067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.